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CObjectives: Discounting has long been a matter of controversy in the
field of health economic evaluations. How to weigh future health ef-
fects has resulted in ongoing discussions. These discussions are immi-
nently relevant for health care interventions with current costs but
future benefits. Different approaches to discount health effects have
been proposed. In this study, we estimated the impact of different
approaches for discounting health benefits of human papillomavirus
(HPV) vaccination. Methods: An HPV model was used to estimate the
mpact of different discounting approaches on the present value of
ealth effects. For the constant discount approaches, we varied the
iscount rate for health effects ranging from 0% to 4%. Next, the impact
f relevant alternative discounting approaches was estimated, includ-
ng hyperbolic, proportional, stepwise, and time-shifted discounting.
esults: The present value of health effects gained through HPV vac-
ination varied strongly when varying discount rates and approaches.
he application of the current Dutch guidelines resulted in a present O
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oi:10.1016/j.jval.2012.01.005alue of health effects that was eight or two times higher than that
roduced when using the proportional discounting approach or when
sing the internationally more common 4% discount rate for health
ffects, respectively. Obviously, such differences translate into large
ariations in corresponding incremental cost-effectiveness ratios.
onclusion: The exact discount rate and approach chosen in an eco-
omic evaluation importantly impact the projected value of health
enefits of HPV vaccination. Investigating alternative discounting ap-
roaches in health-economic analysis is important, especially for vac-
ination programs yielding health effects far into the future. Our study
nderlines the relevance of ongoing discussions on how and at what
ates to discount.
eywords: discounting, health gains, HPV vaccination, QALY.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In economic evaluations of health interventions, typically a com-
parison between competing programs ismade [1-3]. By comparing
wo or more programs, differences in costs and health outcomes
an be estimated. The latter are often expressed in quality-ad-
usted life-years (QALYs) gained. This comparison can be summa-
ized in the incremental cost-effectiveness ratio (ICER), expressed
s incremental costs per QALY gained. This ICER is calculated by
ividing the estimated difference in costs by the estimated differ-
nce in health outcomes. By relating the ICER to a relevant thresh-
ld, health care decisionmakers can subsequently judge the desir-
bility of funding a certain health intervention.
To secure the quality and comparability of health-economic
valuations, many countries have established national guidelines
or such analyses. These guidelines, for example, specify the ap-
ropriate study perspective and indicate how specific costs and
ealth effects should bemeasured and valued. Furthermore, these
* Address correspondence to: Tjalke A. Westra, Department of M
enter Groningen, University of Groningen, HPC EB88, PO Box 30.0
E-mail: t.a.westra@umcg.nl.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.uidelines often specify how future costs and health benefits need
o be weighed relative to current costs and benefits (i.e., how to
iscount and at which discount rate). While all country-specific
uidelines known to us advice the use of the same stationary (or
onstant) discount model, the recommended discount rates for
osts and health outcomes differ from one country to the next.
able 1 gives an overview of the discount rates applied for costs
nd health outcomes for a number of Western countries [4]1.
road consensus exists on the discounting ofmonetized costs and
enefits. By contrast, which methods to use to discount nonmon-
tized health outcomes relative to money has been a topic of con-
iderable controversy for decades.
Vaccination programs against infectious diseases, but also
ther preventive programs, often involve dominant intervention
osts occurring years before the health effects emerge. Although,
o a certain degree, this is intervention specific and disease spe-
ific, generally the discounting method and rate do determine the
eight that future health outcomes of vaccination programs re-
al Microbiology, Molecular Virology Section, University Medical
roningen 9700 RB, The Netherlands.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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563V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 6 2 – 5 6 7ceive in an evaluation [5,6]. With costs being borne in the present
and health effects often far in the future, discounting has a large
impact on the final cost-effectiveness ratio of such programs, in-
creasing the ratio compared with the undiscounted ratio. One of
the most extreme examples relates to vaccination against hu-
man papillomavirus (HPV), for which the major health gains of
interest start to occur approximately 30 years after the initial
vaccination through the prevention of cervical cancer and as-
sociated morbidity and mortality. For instance, Brisson et al. [7]
etermined the age-specific undiscounted and discounted net
resent value of HPV vaccination. Specifically, these authors
howed that especially in the older age groups health gains of
reventing cervical cancer are strongly affected by discounting.
onsequently, the cost-effectiveness of HPV vaccination, which
as recently gained considerable attention in many countries
articularly with regard to the issue of whether or not to fund
large-scale) vaccination programs, is highly sensitive to dis-
ounting [5].
The ICERs of preventive interventions such as vaccination are
o heavily influenced by discounting [8] that the uncertainty re-
ated to methodological disagreement between economists on
his issue can lead to opposite conclusions and decisions. There-
ore, some researchers have argued that specific discounting rules
hould be applied for preventive interventions or for exploring the
ecision uncertainty related to discounting [9]. Recently, Beutels
t al. [10] suggested that alternative discounting approaches using
rates decreasing over time, such as hyperbolic or stepwise dis-
counting, should be applied in sensitivity analyses, which was
previously suggested by Bleichrodt and Brouwer [11]. This should
then provide an insight into whether and to which extent the
choice of the discounting procedure (over which economists dis-
agree) would influence the policy decision based on the economic
evaluation. Naturally, it ismore likely for preventive interventions
(with long-term health impacts) than for curative interventions
(with short-term health impacts) that the choice of one specific
discountingmethod could be decisive in judging the interventions
to be cost-ineffective or cost-effective.
In this article, we aimed to provide an overview of alternative
discounting approaches proposed in the literature. Furthermore,
we investigated the impact of adopting these different discounting
approaches in the context of the economic evaluation of a partic-
ular preventive program (i.e., prophylactic HPV vaccination in the
Netherlands [5]). Given that the health outcomes of HPV vaccina-
tion for the prevention of cervical cancer occur several decades
after the initial vaccination (see Figure 1), this preventive interven-
ion provides an excellent example—possibly one of the most ex-
reme ones—to demonstrate the influence of different discount-
Table 1 – Country-specific discount rates for costs and
health outcomes.
Country Discount rate (%)
Costs Health
Austria 5 5
Belgium 3 1.5
Canada 5 5
England and Wales 3.5 3.5
France 0, 3, 5 0, 3, 5
Germany 3 3
Switzerland 2.5, 5, 10 2.5, 5, 10
Sweden 3 3
The Netherlands 4 1.5
United States 3 3ng approaches.Methods
To investigate the influence of different discount rates and ap-
proaches, we used a previously published in-house Markovmodel
for HPV infection [5]. This model simulates the transmission of
HPV infection through cervical intraepithelial neoplasia stages to
cervical cancer. By simulating a cohort twice, once as an unvacci-
nated cohort and once as a vaccinated cohort, the age-specific
health gains of HPV vaccination can be estimated by considering
the differences between both simulations.
We investigated five discounting approaches and focused on
changing discount rates and approaches for health effects.We did
not vary the discount rate for costs in the current study (whichwill
be set at a constant level of 4% according to Dutch guidelines), and
thus emphasize the differences in the net present value of health
effects depending on different discounting approaches and rates.
Below we summarize the different approaches used for discount-
ing of health effects that were considered in this study.
Constant discounting approach
The constant (or stationary) discounting approach (Equation 1) is
well founded in economic theory and reflects the most generally
used and accepted discounting approach for future costs and
health outcomes in health-economic evaluations [12]. In the con-
stant discounting approach, future costs and health outcomes are
devalued at a constant rate. So, both future costs and health out-
comes are exponentially devalued to themoment the intervention
(e.g., the vaccination) took place. The magnitude of the discount
rate for costs is commonly informed by the rate of return on risk-
free government bonds, in linewith the societal perspective that is
often used. Furthermore, the discount rate for costs is usually de-
termined by this interest rate after correcting for the deflator (i.e.,
the real interest rate is used instead of the nominal rate). A dis-
count rate of 3% to 5% for costs is most often used internationally
(Table 1). In the Netherlands, this discount rate is 4%. Most coun-
tries prescribe the same discount rate for health effects (i.e., uni-
form discounting; e.g., 4% for costs and 4% for health effects). The
reason for this is especially that it has been argued that inconsis-
tencies might occur if discounting is done nonuniformly or differ-
entially [13]. Yet, others have rejected the idea that differential
discounting would be impossible based on grounds of consistency
[8,9]. Indeed, it has been argued that health outcomes could well
be discounted with a lower discount rate than costs, without risk-
ing inconsistency [14-20]. The justification of a lower (but still con-
Cervical cancer is the second most common cancer worldwide. Infection with the Human 
PapillomaVirus (HPV) is a prerequisite for cervical cancer, and the persistence of the 
infection is especially important. In particular, infection with one of the oncogenic types of 
HPV may develop into cervical intraepithelial neoplasia (CIN) of grades I – III and 
ultimately into invasive cancer. Major oncogenic serotypes are 16, 18, 31, 33, 45, and 52.
Of these serotypes, HPV 16 and 18 have shown to be responsible for approximately 
70% of cervical cancer cases worldwide. 
In the Netherlands, HPV infection peaks are found in women aged  20 – 25 years. 
Although most women are able to clear the infection within one year, some of them will 
develop persistent infection. Women can develop CIN I – III and cervical cancer after 
some years of persistent infection. In the Netherlands the average age of cervical cancer 
is estimated between 40 – 45 years.  
Currently, highly effective prophylactic HPV vaccines are available. HPV vaccines are 
most effective if administered to women who are HPV negative.  Therefore, women 
should be vaccinated before they become sexually active. Most developed countries 
decided to implement HPV vaccination of girls aged 12-years in National immunization 
programmes. 
Health benefits following HPV-vaccination comprise of prevention of cervical 
intraepithelial neoplasia or development of cervical cancer. These health benefits are 
expected to occur approximately 20 and 30 years after the initial immunization, 
respectively. Fig. 1 – Pathogenesis of cervical cancer.
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564 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 6 2 – 5 6 7stant in time) discount rate for health outcomes lies in the growth
of the value of health effects over time, which is not otherwise
accounted for in economic evaluations. The difference between
the discount rate for costs and effects would be the expected
growth rate in the value of health. In the Netherlands, this growth
rate has been estimated to be 2.6% [21]. With a discount rate of 4%
for costs, this would imply an appropriate discount rate of 4.0 –
2.5  1.5% for effects. In the Netherlands, a discount rate of 1.5%
or health effects is indeed currently used in differential discount-
ng. In the present study, to illustrate the impact of the discount
ate for health outcomes, we applied different discount rates for
ealth, specifically 0%, 1.5%, 3%, and 4%, while the discount rate
or costs was set at 4%.
(t)
1
1 rt
(1)
where a(t) is the weight attached to time t and r is the discount
rate.
Empirical discounting approaches
In contrast to the constant discounting approach, empirical studies
have shown that the individuals’ time preference may decline over
time, both from an individual and a societal perspective [22-25]. This
was recently confirmed for health effects in ameta-regression anal-
ysis by Asenso-Boadi et al. [25]. In particular, the time preference for
a short-term delay (i.e., a 5-year delay) was approximately 25%,
which decreased to approximately 3.5% for a long-term delay (i.e., a
100-year delay). Alternative discounting approaches have been pro-
posed to better reflect such observed time preferences. Two promi-
nent examples are hyperbolic (Equation 2) and proportional (Equa-
tion 3) discounting [26-28]. Applying these discounting approaches
obviously still implies that future health effects are weighed less
than current ones, although at a decreasing incremental rate. This
could more appropriately capture the exact nature of time prefer-
ence as conceived by the public in the real world.
a(t)
1
1 gth⁄g
(2)
(t) bb t

(3)
Hyperbolic discounting (Equation 2) has been proposed by Loew-
enstein and Prelec [28]. In Equation 2, h reflects the individual’s
preference for the future or timing in general. An individual does
not have any time preference (i.e., a discount rate of 0) if h  0; by
increasing h, the preference for the present increases. Parameter g
determines how much the function differs from the constant dis-
countingmodel [29], with g 1 actually representing the constant
discount model. Proportional discounting (Equation 3) has been
proposed by Harvey [27]. In Equation 3, b reflects themagnitude of
the time preference and  determines the shape of the curve. Ini-
tially, Harvey suggested that  should be 1, but others have intro-
uced different values for . For example, Cairns and van der Pol
24] estimated that the proportional discounting model would fit
mpirical data best if  would be set at 1.5.
Here, the proportional and hyperbolic discounting approaches
were fitted to time preference rates as reported by Asenso-Boadi
et al. [25] by varying the values of the variables to minimize the
sum of squares andmaximize the explanatory power (reflected in
r2) [25]. In particular, for the hyperbolic discounting approach, the
values of h and gwere estimated at 0.32 and 0.29, respectively. Forthe proportional discounting approach, the values of b and were
estimated at 3.4 and 1.1, respectively.
Stepwise approaches
In the stepwise discounting approach, a constant discount rate
is used during a specified period, but this is lowered in subse-
quent consecutive time periods. (It thus resembles a discontin-
uous hyperbolic discounting function.) Stepwise discounting
was previously recommended by the UK treasury (in 1996), and
it has also been mentioned as one of the options for discounting
in economic evaluations in at least two recent articles [10,19,30].
For the United Kingdom, the time intervals after which the dis-
count rate decreases at 0.5% were based on empirical data [31],
and a normative framework was the starting point of the anal-
ysis. We applied the rates recommended by the UK treasury
(i.e., 3.5% for years 0–30, 3% for years 31–75, 2.5% for years 76–
125, 2% for years 126–200, 1.5% for years 201–300, and 1% there-
after). Note, in the static HPV model that we used, the time
horizon of our analyses was set at 100 years, and so the mini-
mum discount rate applied was 2.5%.
Time-shifted approach
Specifically for vaccines, in an attempt to appropriately value the
outcomes of evaluations of preventive interventions, it has been
proposed that the health outcomes might be discounted from the
moment of risk reduction (i.e., averted infections) instead of from
the moment that health is actually gained [32,33]. Bos and col-
leagues argued that in the case of a vaccination program health
gains of preventing infections are undervalued because of dis-
counting, in particular for some infectious diseases with a long-
term delay between the initial infection and disease development.
To account for this, they recommended the time-shifted discount-
ing approach, by which health outcomes are discounted from the
moment the infection is prevented rather than from the moment
each individual life year or QALY is gained. Although this method
has been used by others as a pragmatic discounting approach, an
exact underpinned normative rationale for it has not been given.
Furthermore, this method can easily be criticized because the in-
dividuals’ time preference in the period after an infection is pre-
vented is ignored. Still, we used this method with two discount
rates (4% and 1.5%) in the period in which discounting is required
according to the method. Specifically, QALY losses due to cervical
cancer were discounted only in the period between vaccination
and the moment of HPV infection in the time-shifted approach
(i.e., all QALY losses were implicitly assumed to have been pre-
vented at the same time as the causal factor, anHPV infection,was
prevented).
Table 2 summarizes the five approaches introduced above.
Results
All five discounting approaches were applied to the health out-
comes of a Dutch HPVmodel. Thismodel predicts the incidence of
cervical intraepithelial neoplasia and cervical cancer incidence
with and without HPV vaccination, reflecting the current Dutch
situation. The implementation of HPV vaccination for the full co-
hort of 12-year-old Dutch girls (i.e., cohort size was set at 100,000)
resulted in an undiscounted lifetime gain of 2907 life-years or 3462
QALYs. The total undiscounted costs of implementing HPV vacci-
nation to the Dutch National Immunization program (“Rijksvacci-
natieprogramma”) were €31.5 million (€30.9 million discounted)
and resulted in €11.5 million undiscounted cost offsets (€2.8 mil-
lion discounted).
The application of the different discounting approaches for
health gains resulted in different numbers of discounted QALYs
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565V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 6 2 – 5 6 7gained by HPV vaccination. Figure 2 illustrates the time-specific
iscount rates of the different discount approaches applied.
learly, when applying the proportional or hyperbolic discounting
pproach, the short-term gains are highly devalued; however, the
ong-term benefits are discounted with a relatively lower discount
ate compared with a constant discount rate at 4%. Figure 3 illus-
rates the age-specific net present value of the health gains of HPV
accination when applying the different discounting approaches.
he time-shifted discounting approach resulted in the highest
resent value of QALYs while the proportional or hyperbolic dis-
ounting approach resulted in the lowest estimates (Table 3). Ob-
iously, these results are driven by the relatively high initial dis-
ount rates in these latter two methods (i.e., much higher than
%). If onewould use lower rates in a hyperbolic discount function
e.g., Meerding et al. [34] recently reported empirically observed
yperbolic discounting with relatively low discount rates), this
ould yieldmuch higher net present health benefits. For instance,
pplying these two approaches, but now starting at a 4% discount
ate, we find a net present value of 1613 and 1607 QALYs for the
roportional and hyperbolic discounting approach, respectively.
otably, in the time-shifted discounting approach [32], health out-
omes of HPV vaccination were discounted at a constant rate only
or the period between vaccination and infection, and in the pe-
iod after infection a zero discount rate was applied.
When the stepwise discounting approach was applied, the to-
al number of discounted QALYs were comparable to those ob-
ained at a constant rate of 3%. Note that the total number of
iscounted QALYs is sensitive to the time interval and decline in
iscount rate.
When the conventional constant discounting approach was
pplied, the present value of QALYs gained was highly sensitive
o the chosen discount rate. Lower discount rates for health
utcomes resulted in substantial increases in the total number
f discounted QALYs gained with HPV vaccination (Table 3).
To give an indication of the impact of these different ap-
roaches on the final ICER, we also combined these results with
he discounted costs (4%). It should be noted that we do this
ainly for illustrative purposes and that it might not always be
ogical to combine our results on health gainswith a cost-estimate
ased on constant discounting using a 4% discount rate. In partic-
lar, if one prefers an empirically based approach such as hyper-
olic discounting for health effects, it is likely that one also wishes
o discount costs on a similar basis, that is, using a hyperbolic
iscount function. Table 3 shows the results for the ICERs. Accord-
ng to Dutch guidelines (constant discount rates of 4% for money
nd 1.5% for health; i.e., differential discounting), we found an
CER of €18,400 per QALY gained for HPV vaccination. Further-
ore, varying the discount rate for health effects from 0% to 4%
Table 2 – Overview of different discounting approaches.
Approach Name Description
1 Constant Discount rate is constant over
time (Equation 1), can be
uniform or differential
2 Stepwise Discount rate declines stepwise
after specific time intervals
(Table 2)
3 Hyperbolic Discount rate declines gradually
over time (Equation 2)
4 Proportional Discount rate declines gradually
over time (Equation 3)
5 Time-shifted Time period between vaccination
and the prevention of infection
is discounted rather than full
period up to actual quality-
adjusted life-year gainsesulted in estimated ICERs of €7,600 to €59,100 per QALY, stillsing constant discounting. When we applied the proportional
iscounting approach to health effects, we found an ICER that was
ine times higher than the benchmark of €18,400 perQALY gained.
rgo, extremely large and relevant differences in the ICER were
ound between the various approaches investigated, moving from
xtremely cost-effective up to extremely cost-ineffective (when
ompared with commonly cited thresholds).
Discussion
Discounting of health outcomes is controversial and has been the
subject of extensive debate since it was introduced and recom-
mended for economic evaluations. These discussions often evolve
around uniform or differential discounting of health outcomes
and money, the exact rate of discounting, and whether or not to
use decreasing discount rates. Different discounting approaches
have been suggested. For example, it has been proposed to take
the individual’s time preference more explicitly into account or to
apply lower discount rates in later periods. The aim of using such
alternative methods in applied economic evaluations would be to
explore the decision uncertainty associatedwith the different pre-
vailing opinions on this matter [10]. It has been suggested to in-
clude alternative discount approaches in national guidelines
[10,11]. In particular, it was proposed to apply alternative discount
approaches in sensitivity analyses. In the current study, we eval-
uated the influence of using different discounting approaches for
health outcomes. We illustrated what the impact is of alternative
discounting approaches on future health outcomes and the cost-
effectiveness of HPV vaccination. Because the health outcomes
related to HPV vaccination are expected to occur several decades
after the initial vaccination, the number of QALYs gained by HPV
vaccination is highly sensitive to the discounting method that is
applied [5]. Here, we compared the standard constant discounting
to alternative approaches.
Indeed, our results show that alternative discounting approaches
devalue the long-termhealth outcomes of HPV vaccination very differ-
ently compared with the constant discounting approach. For these al-
ternative discounting approaches, the valuation of future health out-
Fig. 2 – Time-specific discount rates of the different
discount approaches applied.Black squares denote
the constant discounting approach (4%), dark gray dots
the stepwise discounting approach, light gray triangle the
time-shifted discounting approach (4%), and black triang-
les the hyperbolic discounting approach. Note that for the
time-shifted approach, here we assumed that the infection
was prevented 10 years after the intervention. The
proportional and hyperbolic discounting approach followed
similar patterns.
566 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 6 2 – 5 6 7comes was dependent on both the parameter values used in the
discounting approaches and the nature of the approaches themselves.
Obviously, the variation identified in the net present value of QALYs
gained had a large impact on the actual ICERs (Table 2).
Our current model represents a static model that does not ex-
plicitly simulate the spread of HPV in the population. Models that
do simulate this spread explicitly are labeled dynamic transmis-
sionmodels [9,35]. As argued, for interventions that impact on the
transmission dynamics of infectious diseases, it is preferable to
use a dynamic transmissionmodel for the simulation of infectious
diseases [10,35]. In the current article, we illustrate the effect of
different discounting approaches in the static approach. Never-
theless, how to apply constant discounting or alternative ap-
proaches in a dynamic transmission model framework is of high
interest. Because herd immunity induced by HPV vaccination is
highly associated with age (young people tend to have sex with
partners of similar age), one can speculate that the qualitative
impacts of the various discounting techniques are roughly similar
between dynamic and static models when the same vaccination
and screening strategies are compared (i.e., vaccinating a single
cohort every year). Once vaccination starts, in addition to a static
model, a dynamic model projects the prevention of infections in
unvaccinated people. The consequences (warts, precancerous le-
sions, cancer cases, and deaths prevented) of these additional pre-
ventions, however, are likely to follow a pattern over time that is
similar for vaccinated (directly protected) girls and for unvacci-
nated (indirectly protected) girls and boys, mainly because they
are all of similar age. This contrasts with some childhood vaccina-
tions for which the herd effects reach across generations. Never-
theless, the herd immunity benefit in the population induced by
HPV vaccination depends on the proportion of vaccinated individ-
uals in the population. As a consequence, the health gain and the
cost-effectiveness of HPV vaccination might vary between vac-
cinated cohorts until a new steady state has been reached. In
addition, it has been shown that for multicohort models the
cost-effectiveness ratio will change for vaccinated cohorts from
year to year if differential discounting is applied [36-38]. In par-
ticular, HPV vaccination becomes more favorable if additional
Fig. 3 – Age-specific health gains of HPV vaccination in the D
time-shifted discounting approach, a 4% discount rate for th
used. HPV = human papillomavirus.cohorts are vaccinated.In general, it seems important for decision-making and
guideline-prescribing bodies in different jurisdictions to have
transparent, defendable, and plausible discount rules. Constant
uniform discounting is well founded in economic theory, and it
is the generally accepted and recommended discounting ap-
proach. It purposely does not reflect commonly observed de-
clining time preference of individuals, because this enhances
stability by avoiding time inconsistency and paradoxes in policy
making. It has been argued, however, that it can be adjusted to
account for the growing value of health over time [19,39]. There-
fore, constant differential discounting has been proposed,
which allows for a lower discount rate for health effects relative
to costs to adjust for the growing value of health over time
[9,19]. Differential discounting, which has been adopted in some
current (e.g., The Netherlands and Belgium) and previous (e.g.,
United Kingdom) Health Technology Assessment guidelines, of-
ten significantly lowers the ICERs of interventions. In particular,
the ICER of interventions with health gains in the (far) future is
more favorable when differential discounting is applied. Again,
given the impact that discounting has on final outcomes, the
simulation model using different approaches. For the
riod between intervention and prevented infection was
Table 3 – Discounted health outcomes of HPV
vaccination using the different discounting approaches.
Discounting approach QALYs gained ICER (€/QALY)
Undiscounted 3462 7,600
Constant 1.5% 1423 18,400
Constant 3% 715 37,000
Constant 4% 438 59,100
Proportional 164 165,400
Hyperbolic 160 164,500
Stepwise* 718 36,800
Shifted 4% 2117 13,200
Shifted 1.5% 2811 9,400
HPV  human papillomavirus; ICER  incremental cost-effective-
ness ratio; QALY  quality-adjusted life-year.utch
e pe* As proposed by the UK treasury.
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567V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 6 2 – 5 6 7exact underpinning of the discount rules adopted in studies and
prescribed in guidelines needs to be fully transparent. Although
the topic which discounting approaches to consider as most
appropriate is beyond the scope of this article, it must be noted
that some approaches appear to have a better normative and/or
empirical underpinning than do others. Nevertheless, because
discounting strongly affects the present value of costs and out-
comes especially of interventions with long-term outcomes, al-
ternative discount approaches should be applied in sensitivity
analysis. For example, differential discounting or stepwise dis-
counting should be investigated. Recently, the United Kingdom
already recommended lowering the discount rate of outcomes
from 3.5% to 1.5% when health outcomes extend beyond 30
years in sensitivity analysis [40].
Proportional and hyperbolic discounting approaches are important
because they reflect individual and societal timepreferences for health
outcomes [24]. Caution, however, is required in their use because these
odels introducerisk timeof time-inconsistentbehavior.Furthermore,
mpirical studies show high variance in time preference, and the high
bserveddiscount ratesmay result inpolicies thatunfairlyharmfuture
enerations. Still, it is useful to use themmore frequently in economic
valuations, for instance, in sensitivity analyses [11,39]. This is also in-
teresting, because the approach of differential discounting, as pre-
scribed in the Netherlands, and the proportional and hyperbolic dis-
counting functions more or less represent extremes in terms of
outcomes. Thus, using them in sensitivity analysis also would make
sense and be informative for decisionmakers.
Our results highlight the importance of discounting and ongo-
ing discussions in the literature on this topic. Furthermore, our
study underlines the importance of discount rates as well as dis-
count approaches. It illustrates that the recommendation to care-
fully identify appropriate discount methods and rates, and to in-
vestigate the sensitivity of results to the application of alternative
discounting approaches, holds even stronger if vaccination pro-
grams are considered with health effects far into the future. HPV
vaccination can be considered as one of the most extreme exam-
ples of such a program.We hope that this article will contribute to
the debate in this area and to a fair discounting practice, such that
all interventions for cure and prevention can be compared at the
same level playing field.
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